Zeo Scientifix Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Zeo Scientifix Inc (BPSR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Zeo Scientifix Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 7M vs 226M combined for tracked competitors (3.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+47.8% annualized vs trailing 12 months), vs decelerating (-67.2%) for its tracked peer group.
- Growth: Zeo Scientifix Inc generated 124.6% revenue growth year over year in Q2 2026, vs -82.8% for its tracked competitors combined.
- Profitability: Its -5.6% net margin compares with -1,014.8% for the peer group.
- Peer revenue share: Zeo Scientifix Inc accounted for 12.3% of combined revenue among its tracked peer group, up from 1.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.35M compares with $0.27M for the peer group (1.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BPSR Sales vs. its Competitors, Q2 2026
Zeo Scientifix Inc reported revenue growth of 124.63 % year on year in Q2 2026, above its competitors' combined revenue change of -82.83 %.
With a net margin of -5.62 %, Zeo Scientifix Inc achieved higher profitability than its competitors (-1,014.81 %).
Zeo Scientifix Inc generated 12.26 % of the combined sales of its peer group, up from 1.06 % a year earlier.
Zeo Scientifix Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Zeo Scientifix Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Zeo Scientifix Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Zeo Scientifix Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 124.6% for Zeo Scientifix Inc. Zeo Scientifix Inc's share of combined industry revenue moved from 0.00% to 0.01%, a gain of 0.00 percentage points.
Zeo Scientifix Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Zeo Scientifix Inc | No | Yes | Yes | No |
| Competitors combined (10) | ||||
| High-Confidence Competitors (1) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BPSR Stock Performance relative to its Competitors
BPSR Stock Performance relative to High-Confidence Competitors
BPSR Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Fate Therapeutics Inc | 282.9% | Outperformed |
| 2 | Brainstorm Cell Therapeutics inc | 282.9% | Outperformed |
| 3 | Aura Biosciences Inc | 282.9% | Outperformed |
| 4 | Mesoblast Limited | 282.9% | Outperformed |
| 5 | Regenxbio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Zeo Scientifix Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Zeo Scientifix Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Zeo Scientifix Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Zeo Scientifix Inc | 0.47 | 6.99 |
| Mesoblast Limited | 1,751.30 | 17.20 |
| Aura Biosciences Inc | 583.41 | - |
| Regenxbio Inc | 396.03 | 174.48 |
| Fate Therapeutics Inc | 286.55 | 6.49 |
| Lineage Cell Therapeutics Inc | 253.89 | 13.08 |
| SUBTOTAL | 3,472.63 | 353.70 |
Sign in to see all competitors of Zeo Scientifix Inc .
Sources: Zeo Scientifix Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Zeo Scientifix Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Zeo Scientifix Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Exocel Bio | Named by the company | 85% |
| Liveyon Labs | Named by the company | 85% |
| Re-gen Active Lab | Named by the company | 85% |
| DermaSciences | Named by the company | 85% |
| Kimera Labs | Named by the company | 85% |
| Platinum Biologics | Named by the company | 85% |
| Utah Cord Bank | Named by the company | 85% |
| Benev Company Inc. | Named by the company | 85% |
| Frontier Biologics | Named by the company | 85% |
| MiMedix Group, Inc. | Named by the company | 85% |
| Regenexx | Named by the company | 85% |
| Direct Biologics | Named by the company | 85% |
| Liveyon | Named by the company | 85% |
| Predictive Biotech | Named by the company | 85% |
| Vitti Labs | Named by the company | 85% |
| Cord for Life | Named by the company | 85% |
| Invitrx Therapeutics | Named by the company | 85% |
| Neobiosis | Named by the company | 85% |
| Signature Biologics | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Zeo Scientifix Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Zeo Scientifix Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Zeo Scientifix Inc | 0 | 349,350 | -194,200 |
| Mesoblast Limited | 1,751 | 159,241 | -945,759 |
| Aura Biosciences Inc | 583 | - | -1,159,389 |
| Regenxbio Inc | 396 | 470,302 | -529,466 |
| Fate Therapeutics Inc | 287 | 40,317 | -782,584 |
| Lineage Cell Therapeutics Inc | 254 | 169,909 | -416,948 |
| PEERS TOTAL | 3,472 | 266,087 | -441,429 |
Sign in to see all peers for Zeo Scientifix Inc .
Zeo Scientifix Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Zeo Scientifix Inc's industry classification, broader than the peer set above. Market cap in millions of $.Zeo Scientifix Inc ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Zeo Scientifix Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Zeo Scientifix Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2021-11-05.
Zeo Scientifix Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 81.52 % | 68.46 % (avg) | +13.1 pp |
| Operating Margin | -59.10 % | industry median | +144.4 pp |
| EBITDA Margin | -53.71 % | -0.94 % (avg) | -52.8 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 6.74 % (avg) | -6.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Zeo Scientifix Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 14.71 % | 96.40 % | 67.65 % | 56.37 % | -22.14 % | -1.85 % | 21.93 % |
| Operating Margin | -487.94 % | 115.51 % | -97.87 % | -534.29 % | -106.73 % | -123.93 % | -118.74 % | -90.21 % |
| Return on Invested Capital | 84.82 % | -66.82 % | 71.81 % | 522.08 % | 121.96 % | 309.42 % | 164.86 % | 165.35 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Zeo Scientifix Inc's Strategic Group Map
Every company in Zeo Scientifix Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Zeo Scientifix Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Zeo Scientifix Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Zeo Scientifix Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Zeo Scientifix Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Zeo Scientifix Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Zeo Scientifix Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Zeo Scientifix Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 144.4 points above the industry median.
- Return on equity 442.4 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+47.8% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-67.2% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Zeo Scientifix Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Zeo Scientifix Inc | 0.20 | 0.49 | - |
| Mesoblast Limited | 1.57 | 1.99 | 0.09 |
| Aura Biosciences Inc | 3.53 | 10.44 | - |
| Regenxbio Inc | 0.54 | 2.61 | - |
| Fate Therapeutics Inc | 2.20 | 6.02 | - |
| Lineage Cell Therapeutics Inc | 4.19 | 5.70 | - |
Sign in to see all peers for Zeo Scientifix Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Zeo Scientifix Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Zeo Scientifix Inc | Q1 2026 | +124.6 % | - |
| Mesoblast Limited | Q2 2025 | +191.4 % | - |
| Aura Biosciences Inc | Q2 2026 | - | - |
| Regenxbio Inc | Q2 2026 | +405.7 % | - |
| Fate Therapeutics Inc | Q2 2026 | +9.2 % | - |
| Lineage Cell Therapeutics Inc | Q2 2026 | -61.3 % | - |
| PEERS TOTAL | +201.4 % | - |
Sign in to see all peers for Zeo Scientifix Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Zeo Scientifix Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Zeo Scientifix Inc | Q1 2026 | +105.5 % | - |
| Mesoblast Limited | Q2 2025 | - | +150.9 % |
| Aura Biosciences Inc | Q2 2026 | - | -46.2 % |
| Regenxbio Inc | Q2 2026 | - | +94.4 % |
| Fate Therapeutics Inc | Q2 2026 | - | -94.1 % |
| Lineage Cell Therapeutics Inc | Q2 2026 | - | +671.4 % |
Sign in to see all peers for Zeo Scientifix Inc .
Zeo Scientifix Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Zeo Scientifix Inc | - | - | - |
| Mesoblast Limited | - | - | - |
| Aura Biosciences Inc | - | - | - |
| Regenxbio Inc | - | - | - |
| Fate Therapeutics Inc | - | - | - |
| Lineage Cell Therapeutics Inc | - | - | - |
Sign in to see all peers for Zeo Scientifix Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Zeo Scientifix Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Zeo Scientifix Inc | - | 0.07 |
| Mesoblast Limited | - | 101.83 |
| Aura Biosciences Inc | - | - |
| Regenxbio Inc | - | 2.27 |
| Fate Therapeutics Inc | - | 44.15 |
| Lineage Cell Therapeutics Inc | - | 19.41 |
| PEERS AVERAGE | - | 9.82 |
Sign in to see all peers for Zeo Scientifix Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.